Abcellera Biologics Inc. · NASDAQ:ABCL

Abcellera Biologics — Q2 2023 Earnings Presentation

14 slides from Abcellera Biologics's earnings presentation, Aug 3, 2023

1. Slide 1: Q2 2023 Business Update

   Q2 2023 BUSINESS UPDATE AUGUST 3, 2023 COPYRIGHT © ABCELLERA

2. Slide 2: Disclaimer

   DISCLAIMER This presentation contains forward-looking statements, including These statements involve risks, uncertainties and other factors that may statements made pursuant to the safe harbor provisions of the Private cause actual results, levels of activity, performance, or achievements to be Q2 2

3. Slide 3: Continued progress in building AbCellera's high-value portfolio

   Q 2 2 0 2 3 . B U S I N E S S U P D AT E S U M M A R Y. CONTINUED $823M in total cash, cash equivalents & marketable securities PROGRESS IN Q2 2023 BUSINESS UPDATE BUILDING 177 cumulative programs under contract ABCELLERA’S 106 cumulative partnered programs started HIGH-VALUE PORTFOLIO 9 COPYRIGHT ©

4. Slide 4: AbCellera's end market is antibody medicines

   M A R K E T O P P O RT U N I T Y. AbCellera’s end market is antibody medicines. Q2 2023 BUSINESS UPDATE Programs Per Year Antibody Discovery ~$6B Therapeutic Antibodies Commercial Antibody Medicines ~$400B COPYRIGHT © ABCELLERA in the Clinic 4

5. Slide 5: AbCellera secures ~$220M in non-dilutive funding to accelerate execution

   AbCellera secures ~$220M in non-dilutive funding to accelerate execution of strategy and bring programs into clinic with high capital efficiency. Q2 2023 BUSINESS UPDATE Lab & Office Discovery & Clinical Total Construction Pre-clinical Studies Project Development Investments ~$220M ~$190M ~$100M ~$5

6. Slide 6: Government funding drives value in multiple dimensions of AbCellera's business

   Government funding drives value in multiple dimensions of AbCellera’s business. Funding will allow us to advance more pre-partnered programs, and we believe Q2 2023 BUSINESS UPDATE success in these programs will drive value in multiple dimensions of our business: Develop platform, Bring programs to

7. Slide 7: Q2 2023 Financials Update

   Q2 2023 COPYRIGHT © ABCELLERA FINANCIALS UPDATE

8. Slide 8: Strong portfolio growth

   FINANCIALS Strong portfolio growth. Cumulative # of Cumulative # of Partnered Program Starts Molecules in the Clinic Q2 2023 BUSINESS UPDATE 106 9 9 110 100 8 Total # of 90 7 80 Programs Under Contract 177 70 6 60 5 50 4 Total # of 40 3 30 Discovery Partners 41 20 2 10 1 0 0 2015 16 17 18 19 20 21 2

9. Slide 9: Molecules in the clinic

   FINANCIALS 9 molecules in the clinic. MOLECULE STAGE THERAPEUTIC AREA PARTNER PROGRAM TYPE bamlanivimab Marketed, Emergency Use • infectious disease: COVID-19 (LY-CoV555) Authorization (EUA) AbCellera FINANCIALS bebtelovimab Marketed, Emergency Use pre-partnered program PARTNERED • infectious diseas

10. Slide 10: $10M total revenue, predominantly from discovery activity

    FINANCIALS $10M total revenue, predominantly from discovery activity. Revenue USD $45.9M ROYALTIES Q2 2023 BUSINESS UPDATE MILESTONES LICENSING RESEARCH FEES $10.1M $0.2M $9.8M COPYRIGHT © ABCELLERA Q2 2022 Q2 2023 10

11. Slide 11: Operating expenses reflect ongoing investments

    FINANCIALS Operating expenses reflect ongoing investments. Operating Expenses USD RESEARCH & DEVELOPMENT SALES & MARKETING GENERAL & ADMIN Q2 2023 BUSINESS UPDATE +$9.8M $36.5M $26.7M +$1.1M $14.4M $15.5M +$0.7M COPYRIGHT © ABCELLERA $3.1M $3.8M Q2 2022 Q2 2023 Q2 2022 Q2 2023 Q2 2022 Q2 2023 11

12. Slide 12: Net loss of $31M; ($0.11) per share

    FINANCIALS Net loss of $31M; equivalent to ($0.11) per share (basic & diluted). Earnings USD NET EARNINGS EARNINGS PER SHARE: BASIC EARNINGS PER SHARE: DILUTED Q2 2023 BUSINESS UPDATE -$6.8M -$0.02 -$0.02 -$30.5M -$0.11 -$0.11 COPYRIGHT © ABCELLERA Q2 2022 Q2 2023 Q2 2022 Q2 2023 Q2 2022 Q2 2023 12

13. Slide 13: Over $800 million in total cash, equivalents, and marketable securities

    FINANCIALS Over 800 million in total cash, equivalents, and marketable securities. Cash Flows USD $915M $823M Q2 2023 BUSINESS UPDATE $500M Marketable Securities $616M Marketable Securities ($24M) $106M Marketable Securities (net) $387M $78M Cash & Other $1M Equivalents ($184M) $0M $180M Cash & Equi

14. Slide 14: Thank you

    14 COPYRIGHT © ABCELLERA Q2 2023 BUSINESS UPDATE YOU THANK

AbCellera Biologics — Q2 2023 Earnings Presentation on 6ix